Published in Hum Vaccin Immunother on March 03, 2016
Angiogenesis in cancer and other diseases. Nature (2000) 28.28
Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol (2001) 25.63
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer (2003) 22.78
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev (2010) 12.60
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol (2007) 9.37
The regulation of IL-10 production by immune cells. Nat Rev Immunol (2010) 9.18
Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature (2006) 8.16
Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst (2007) 7.10
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci U S A (1991) 5.02
Allergy and allergic diseases. First of two parts. N Engl J Med (2001) 4.33
The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer (2007) 4.01
Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science (1990) 3.70
Biological properties of interleukin 10. Immunol Today (1992) 3.62
A hybrid mathematical model of solid tumour invasion: the importance of cell adhesion. Math Med Biol (2005) 3.14
Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev (2001) 3.12
Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med (2014) 2.96
Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res (2005) 2.83
Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad Sci U S A (2000) 2.83
Stromal cells can contribute oncogenic signals. Semin Cancer Biol (2001) 2.80
Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev (2007) 2.69
Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Sci Transl Med (2014) 2.69
Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci U S A (2001) 2.62
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood (2005) 2.60
Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev (2008) 2.52
Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med (2007) 2.29
Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med (2002) 2.25
Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res (2012) 2.09
Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res (2005) 2.06
Dendritic cells as sensors of infection. Immunity (2001) 2.00
Expression cloning and characterization of a human IL-10 receptor. J Immunol (1994) 1.89
Signal transduction for chemotaxis and haptotaxis by matrix molecules in tumor cells. J Cell Biol (1990) 1.89
Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer (2007) 1.77
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol (2006) 1.74
Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A (2010) 1.67
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res (2008) 1.66
Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A (2004) 1.63
The "seed and soil" hypothesis revisited. Lancet Oncol (2008) 1.60
Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res (2003) 1.60
Allergy and allergic diseases. Second of two parts. N Engl J Med (2001) 1.58
Crystal structure of interleukin-10 reveals the functional dimer with an unexpected topological similarity to interferon gamma. Structure (1995) 1.54
A homolog of interleukin-10 is encoded by the poxvirus orf virus. J Virol (1997) 1.51
Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res (1980) 1.47
Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res (2006) 1.47
Bacterial targeted tumour therapy-dawn of a new era. Cancer Lett (2008) 1.44
The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin Oncol (2012) 1.44
Redox regulation of the hypoxia-inducible factor. Biol Chem (2006) 1.40
Structure of the mouse IL-10 gene and chromosomal localization of the mouse and human genes. J Immunol (1992) 1.40
Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans. Adv Immunol (2014) 1.38
Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett (2006) 1.34
Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc Natl Acad Sci U S A (2003) 1.34
Stromal reaction in cancer tissue: pathophysiologic significance of the expression of matrix-degrading enzymes in relation to matrix turnover and immune/inflammatory reactions. Pathol Int (1998) 1.30
Cancer research: past, present and future. Nat Rev Cancer (2011) 1.24
Principles of tumor immunosurveillance and implications for immunotherapy. Cancer Gene Ther (2002) 1.17
Targeting TGF-β signaling in cancer. Expert Opin Ther Targets (2013) 1.16
Effect of histolyticus infection and toxin on transplantable mouse tumors. Proc Soc Exp Biol Med (1947) 1.15
Tuberculosis in acute leukemia: a clinico-hematological profile. Hematology (2006) 1.14
Pharmacologic and toxicologic evaluation of C. novyi-NT spores. Toxicol Sci (2005) 1.14
The regulation of IL-10 expression. Curr Top Microbiol Immunol (2014) 1.09
The genome of equine herpesvirus type 2 harbors an interleukin 10 (IL10)-like gene. Virus Genes (1993) 1.08
Kinetic and thermodynamic studies of the conversion of previtamin D3 to vitamin D3 in human skin. J Biol Chem (1993) 1.07
ARDent about acetylation and deacetylation in hypoxia signalling. Trends Cell Biol (2006) 1.03
Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies. Curr Mol Med (2011) 1.02
Toll-like receptor 4 mediates an antitumor host response induced by Salmonella choleraesuis. Clin Cancer Res (2008) 1.02
Development and function of IL-10 IFN-gamma-secreting CD4(+) T cells. J Leukoc Biol (2009) 1.02
Crystal structure of Epstein-Barr virus protein BCRF1, a homolog of cellular interleukin-10. J Mol Biol (1997) 1.00
The role of interferon gamma in regulation of CD4+ T-cells and its clinical implications. Cell Immunol (2008) 1.00
A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunol Immunother (2012) 0.97
Salmonella choleraesuis as an anticancer agent in a syngeneic model of orthotopic hepatocellular carcinoma. Int J Cancer (2008) 0.96
Evaluation of Clostridium novyi-NT spores in dogs with naturally occurring tumors. Am J Vet Res (2012) 0.95
Interleukin-10 production in malignant melanoma: preferential detection of IL-10-secreting tumor cells in metastatic lesions. Int J Cancer (1996) 0.93
Harnessing the antitumor potential of macrophages for cancer immunotherapy. Oncoimmunology (2013) 0.93
Engineering bacteria toward tumor targeting for cancer treatment: current state and perspectives. Appl Microbiol Biotechnol (2011) 0.93
T cell augments the antitumor activity of tumor-targeting Salmonella. Appl Microbiol Biotechnol (2011) 0.92
Interleukin-10: an important immunoregulatory cytokine with major impact on psoriasis. Curr Drug Targets Inflamm Allergy (2004) 0.91
IFN-gamma promotes generation of IL-10 secreting CD4+ T cells that suppress generation of CD8 responses in an antigen-experienced host. J Immunol (2009) 0.90
Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as a tool for anti-tumor treatment. FEMS Microbiol Lett (2005) 0.90
Overcoming original antigenic sin to generate new CD8 T cell IFN-gamma responses in an antigen-experienced host. J Immunol (2006) 0.90
Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases. J Pharm Pharmacol (2003) 0.88
The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment. J Immunol Res (2014) 0.88
Targeting specific molecular pathways holds promise for advanced gallbladder cancer therapy. Cancer Treat Rev (2015) 0.88
Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: immunological problems and future directions. Cell Immunol (2011) 0.87
Clostridium novyi-NT can cause regression of orthotopically implanted glioblastomas in rats. Oncotarget (2015) 0.86
Macrophages increase the resistance of pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine deaminase. Oncoimmunology (2013) 0.85
Bacteriolytic therapy of experimental pancreatic carcinoma. World J Gastroenterol (2010) 0.85
Manipulating IL-10 signalling blockade for better immunotherapy. Cell Immunol (2015) 0.84
New strategies for cancer gene therapy: progress and opportunities. Clin Exp Pharmacol Physiol (2009) 0.84
IL-10 signalling blockade at the time of immunization inhibits Human papillomavirus 16 E7 transformed TC-1 tumour cells growth in mice. Cell Immunol (2014) 0.83
IL-10 mediates suppression of the CD8 T cell IFN-gamma response to a novel viral epitope in a primed host. J Immunol (2003) 0.82
Graphene oxide absorbed anti-IL10R antibodies enhance LPS induced immune responses in vitro and in vivo. Immunol Lett (2012) 0.82
Regulatory T cells in cancer: an overview and perspectives on cyclooxygenase-2 and Foxp3 DNA methylation. Hum Immunol (2013) 0.81
Inefficacy of therapeutic cancer vaccines and proposed improvements. Casus of prostate cancer. Anticancer Res (2014) 0.80
Interleukin-6, interleukin-10 and heat shock protein-90 expression in renal epithelial neoplasias and surrounding normal-appearing renal parenchyma. Int J Immunopathol Pharmacol (2007) 0.80
Modifying tumor-associated macrophages: An important adjunct to immunotherapy. Oncoimmunology (2013) 0.80
A push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses. Vaccine (2011) 0.80
Autoimmunity heats up. Nat Med (2003) 0.79